AARD — AARDVARK THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying AARD?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 3 tracked investors who changed their AARD position last quarter, 1 bought and 2 sold (33% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +1 tracked investor added or increased positions last quarter (Steve Cohen)
- +3 tracked investors reported holding AARD at their latest filing
- −2 tracked investors reduced or exited last quarter (2 reduced, 0 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About AARDVARK THERAPEUTICS INC (AARD)
AARDVARK THERAPEUTICS INC (AARD) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $18M. Across recent filings, tracked investors recorded 4 new positions, 5 increased, 5 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AARD
How many top investors track AARD
A small number of top investors own this.
AARD Ownership Composition
How AARDVARK THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting AARD
- Ken GriffinSep 30, 2026Citadel AdvisorsShares1MValue$5.4M% Portfolio0.00%
- Izzy EnglanderSep 30, 2026Millennium ManagementShares62.5KValue$329.1K% Portfolio0.00%
- Steve CohenSep 30, 2026Point72 Asset ManagementShares35.5KValue$186.9K% Portfolio0.00%
Recent activity
- Reduced$329.1K(-10.71%)Nov 16, 2026
- Increased$186.9K(55.02%)Nov 16, 2026
- Reduced$5.4M(-24.17%)Nov 16, 2026
- $493KMay 15, 2025
- Sold$0(-100.00%)Aug 14, 2025
- Increased$6.3M(51.22%)Feb 17, 2026
- Reduced$370.7K(-79.66%)May 15, 2026
- Reduced$402.9K(-28.87%)Aug 14, 2026
- New$9.4MMay 15, 2025
- Increased$17.4M(0.76%)Aug 14, 2025
- Increased$18.1M(5.93%)Nov 14, 2025
- Reduced$16.9M(-5.19%)Feb 17, 2026
- Increased$7.7M(3.60%)Aug 14, 2026
- New$484.6KFeb 17, 2026
- Sold$0(-100.00%)May 15, 2026
- New$131.7KAug 14, 2026
Frequently asked questions
- How many institutional investors hold AARD?
- 3 tracked institutional investors disclosed a position in AARD (AARDVARK THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AARD?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in AARD, valued at $18M.
- Did institutional ownership of AARD increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 5 increased, 5 reduced, and 2 fully exited AARD.
- Where does this AARD ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.